Advances and challenges of PET imaging in bladder cancer-An update and future trends.
1/5 보강
Molecular imaging with positron emission tomography (PET) is a powerful tool in the clinical management of bladder cancer, providing functional information that complements conventional anatomical ima
APA
Mena E, Lindenberg L, et al. (2026). Advances and challenges of PET imaging in bladder cancer-An update and future trends.. Seminars in nuclear medicine, 56(2), 200-211. https://doi.org/10.1053/j.semnuclmed.2026.02.004
MLA
Mena E, et al.. "Advances and challenges of PET imaging in bladder cancer-An update and future trends.." Seminars in nuclear medicine, vol. 56, no. 2, 2026, pp. 200-211.
PMID
41775548 ↗
Abstract 한글 요약
Molecular imaging with positron emission tomography (PET) is a powerful tool in the clinical management of bladder cancer, providing functional information that complements conventional anatomical imaging. This review summarizes the current role of PET imaging for bladder cancer care, highlighting the strengths and limitations of FDG, and explores future directions, including emerging non-FDG tracers that target alternative aspects of tumor biology, such as specific receptors, fibroblast activation or Nectin-4 expression, which may improve lesion detectability and better characterize disease leading to more precise treatments. In parallel, we discuss key technological advances, including PET/MRI, integration of quantitative PET with radiomics, and artificial intelligence-driven analysis, all of which hold promises for enhancing diagnostic accuracy, refining risk stratification, and supporting personalized clinical decision-making in bladder cancer management.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.